Placebo + ACI-24.060 at Dose A + ACI-24.060 at Dose B + ACI-24.060 at Dose C + ACI-24.060 at Dose D + Placebo + ACI-24.060 at Dose A + ACI-24.060 at Dose B + ACI-24.060 at Dose C
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Amyloid Plaque
Conditions
Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease, Alzheimer's Disease
Trial Timeline
Jun 21, 2022 → Jun 1, 2026
NCT ID
NCT05462106About Placebo + ACI-24.060 at Dose A + ACI-24.060 at Dose B + ACI-24.060 at Dose C + ACI-24.060 at Dose D + Placebo + ACI-24.060 at Dose A + ACI-24.060 at Dose B + ACI-24.060 at Dose C
Placebo + ACI-24.060 at Dose A + ACI-24.060 at Dose B + ACI-24.060 at Dose C + ACI-24.060 at Dose D + Placebo + ACI-24.060 at Dose A + ACI-24.060 at Dose B + ACI-24.060 at Dose C is a phase 1/2 stage product being developed by AC Immune for Amyloid Plaque. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05462106. Target conditions include Amyloid Plaque, Beta-Amyloid, DSAD.
What happened to similar drugs?
3 of 20 similar drugs in Amyloid Plaque were approved
Approved (3) Terminated (0) Active (17)
Hype Score Breakdown
Clinical
9
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05462106 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Amyloid Plaque
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ZN-d5 | Zentalis Pharmaceuticals | Phase 1/2 | 22 |
| VELCADE | Johnson & Johnson | Phase 1/2 | 32 |
| ABBV-383 (Etentamig) | AbbVie | Phase 1/2 | 39 |
| Venetoclax + Dexamethasone + Daratumumab | AbbVie | Phase 1/2 | 24 |
| Eplontersen Solution for Injection | AstraZeneca | Phase 1 | 29 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 44 |
| Treatment of transthyretin (ATTR) amyloidosis in observational study setting | AstraZeneca | Pre-clinical | 33 |
| Eplontersen | AstraZeneca | Phase 3 | 47 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 44 |
| Carfilzomib + Dexamethasone | Amgen | Phase 1 | 29 |
| Idelalisib | Gilead Sciences | Phase 2 | 27 |
| NNC6019-0001 + Placebo (NNC6019-0001) | Novo Nordisk | Phase 3 | 47 |
| NNC6019-0001 | Novo Nordisk | Phase 2 | 39 |
| NNC6019-0001 + Placebo (NNC6019-0001) | Novo Nordisk | Phase 2 | 35 |
| Coramitug | Novo Nordisk | Phase 1 | 36 |
| Tafamidis | Pfizer | Pre-clinical | 26 |
| Ponezumab | Pfizer | Phase 2 | 35 |
| Fx-1006A + Placebo | Pfizer | Phase 2/3 | 38 |
| Tafamidis | Pfizer | Pre-clinical | 30 |
| tafamidis meglumine | Pfizer | Approved | 43 |